Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
Oral desensitization using crushed sesame seeds and tahini may be a safe and effective method to desensitize pediatric patients with sesame allergy...
Read Full NewsThese were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.
As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.
1.
Best foot forward—chemo care should include podiatry, say researchers
2.
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
3.
Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer
4.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
5.
combating racial discrimination in next-generation breast cancer screening.
1.
Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma
2.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
3.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
4.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
5.
The Basics of M.C.V Normal Range for Better Health Management
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge